| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0411 | (+)-JQ1 | 1268524-70-4 | (+)-JQ1 is a novel, potent and highly specific BET (Bromodomain and extra terminal domain) bromodomain inhibitor with antineoplastic activity. |
![(6s)-4-(4-氯苯基)-2,3,9-三甲基-6H-噻吩并[3,2-f][1,2,4]噻唑并[4,3-a][1,4]二氮杂卓-6-乙酸](http://www.invivochem.com/upload/0201/CgAH6F22jvCAA-_jAAAfcaGjtsE003.png)
|
V3740 | (+)-JQ1 carboxylic acid | 202592-23-2 | (+)-JQ1 carboxylic acid is the free carboxylic acid (COOH) form of (+)-JQ1 (tert-Butyl ester form-COOtBu). |
|
V104879 | (R)-SR-C-107 | (R)-SR-C-107 is an oral acute myeloid leukemia (AML) inhibitor based on ENL (yeast domain-containing protein) inhibitors. | |
|
V52487 | 653-47 hydrochloride | 1224567-46-7 | 653-47 HCl is an enhancer that significantly enhances the cAMP response element binding protein (CREB) inhibitory activity of 666-15. |
|
V2765 | AZD5153 HNT salt | 1869912-40-2 | AZD-5153 HNT salt, the 6-Hydroxy-2-naphthoic acid salt form of AZD5153, is a potent, selective, and orally available BET/BRD4 (bromodomain and extraterminal) bromodomain inhibitor with pKi of 8.3 for BRD4. |
|
V4188 | BAY-850 | 2099142-76-2 | BAY-850 is a novel, potent and isoform selective inhibitor of ATPase family AAA domain-containing protein 2(ATAD2)with anIC50of 166 nM. |
|
V98401 | BET BD2-IN-3 | 2677039-66-4 | BET BD2-IN-3 (Compound I-58) is a BET inhibitor targeting the BD2 domain of BET. |
|
V56140 | BET-IN-19 | 1643947-30-1 | BET-IN-19 (Compound 146) is a BET inhibitor. |
|
V130140 | BI-7273 acid | 2097514-90-2 | BI-7273 acid is a BRD9 PROTAC ligand. |
|
V2909 | BI-9564 | 1883429-22-8 | BI-9564 is a novel, cell-permeable, noncytotoxic, potent, and selective inhibitor of BRD9 (bromodomain-containing protein) and BRD7 BD (bromodomains) with Kd values of 14.1 and 239 nM, and IC50 values of 75 nM and 3.4 µM for BRD9/7 respectively. |
|
V88851 | BMF-219 | 2448172-22-1 | Menin-MLL inhibitor 21 (example 9) is a specific and irreversible inhibitor of Menin-MLL interaction, which can be used for research on autoimmune diseases, xenoimmune diseases, cancer and other diseases that depend on menin-MLL. |
|
V3467 | BMS-986158 | 1800340-40-2 | BMS-986158 (BMS986158; BMS 986158) is a novel, potent and selective BET (bromodomain and extra-terminal) protein inhibitor with potential antineoplastic activity. |
|
V75500 | BN-104 (BNM-1192; Menin-MLL inhibitor 27) | 2938995-50-5 | Menin-MLL inhibitor 27 can inhibit Menin-MLL interaction and may be utilized in cancer-related research, like acute myeloid leukemia. |
|
V75502 | BRD4 Inhibitor-17 | 2835555-10-5 | BRD4 Inhibitor-17 (Compound 5i) is a potent BRD4 inhibitor (antagonist) with IC50 of 0.33 μM. |
|
V90132 | BRD4 Inhibitor-32 | 1445992-86-8 | BRD4 Inhibitor-32 (example 15) is a BRD4 inhibitor that can be used in the research of acute kidney disease and chronic kidney disease. |
|
V110923 | BRD4/BCL6-IN-1 | 3059483-02-9 | BRD4/BCL6-IN-1 (compound I-15) is a dual-target inhibitor of BRD4 (BRD4-BD1 and BRD4-BD2: IC50 < 5 nM) and BCL6 (KD < 1 nM). |
|
V87967 | BRD9 Degrader-4 | 3024541-39-4 | BRD9 Degrader-4 (BRD9c) is a bifunctional molecule and a potent BRD9 degrader with a DC50 value of ≤25 nM. |
|
V130642 | BRDT-IN-1 | BRDT-IN-1 is a BRDT-BD1 and BRDT-T inhibitor with an IC50 of 19 nM, Ki of 8.8 nM, and Ka of 1.6 nM against BRDT-BD1; and an IC50 of 56 nM and Ka of 5.0 nM against BRDT-T. | |
|
V52322 | BRM/BRG1 ATP Inhibitor-3 | 2368901-31-7 | BRM/BRG1 ATP Inhibitor-3 is a BRG1/BRM inhibitor. |
|
V117342 | BRM/BRG1 ATP-IN-7 | 2468048-19-1 | BRM/BRG1 ATP-IN-7 (compound Cpd69) is a selective dual inhibitor that simultaneously inhibits BRM (SMARCA2) and BRG1 (SMARCA4), with IC50 values of 12 nM and 8 nM, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
